E. Bow

Novel Dual-Target μ-Opioid Receptor and Dopamine D3 Receptor Ligands as Potential Nonaddictive Pharmacotherapeutics for Pain Management.

V. Katritch, A. Newman, Alessandro Bonifazi, 2021, Journal of medicinal chemistry.

G-Protein biased opioid agonists: 3-hydroxy-N-phenethyl-5-phenylmorphans with three-carbon chain substituents at C9.

Eugene S. Gutman, J. Deschamps, S. Hassan, 2020, RSC medicinal chemistry.

Bivalent Conjugate Vaccine Induces Dual Immunogenic Response That Attenuates Heroin and Fentanyl Effects in Mice

Z. Beck, G. Matyas, K. Rice, 2021, Bioconjugate chemistry.

Novel Vaccine That Blunts Fentanyl Effects and Sequesters Ultrapotent Fentanyl Analogues

Z. Beck, G. Matyas, K. Rice, 2020, Molecular pharmaceutics.

The Structure–Function Relationships of Classical Cannabinoids: CB1/CB2 Modulation

J. Rimoldi, E. Bow, 2016, Perspectives in medicinal chemistry.

Discovery of a Potent Highly Biased MOR Partial Agonist among Diastereomeric C9-Hydroxyalkyl-5-phenylmorphans

Eugene S. Gutman, T. Prisinzano, J. Bergman, 2023, Molecules.

Role of efficacy as a determinant of locomotor activation by mu‐opioid receptor (MOR) ligands in female and male mice. II. Effects of novel MOR‐selective phenylmorphans with high‐to‐low MOR efficacy

Eugene S. Gutman, D. Selley, A. Sulima, 2023, Pharmacology research & perspectives.